If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
{\displaystyle k_{1}\cdot (PA)^{t}+k_{2}\cdot (PB)^{t}+k_{3}\cdot (PC)^{t}\geq 2^{t}{\sqrt {k_{1}k_{2}k_{3}}}\left({\frac {(PD)^{t}}{\sqrt {k_{1}}}}+{\frac {(PE)^{t}}{\sqrt {k_{2}}}}+{\frac {(PF)^{t}}{\sqrt {k_{3}}}}\right),}
repressor A DNA-binding protein that inhibits the expression of one or more genes by binding to the operator and blocking the attachment of RNA polymerase to the promoter, thus preventing transcription. This process is known as negative gene regulation or repression.
=== Astrophysics === MHD applies to astrophysics, including stars, the interplanetary medium (space between the planets), the interstellar medium (space between the stars), and jets. Most astrophysical systems are not in local thermal equilibrium and therefore require an additional kinematic treatment to describe all the phenomena within the system (see Astrophysical plasma). Sunspots are caused by the Sun's magnetic fields, as Joseph Larmor theorized in 1919. The solar wind, predicted by Eugene Parker, is also described by MHD. The differential solar rotation may be the long-term effect of magnetic drag at the Sun's poles, an MHD phenomenon resulting from the Parker spiral shape of the Sun's extended magnetic field. Previously, theories describing the formation of the Sun and planets could not explain how the Sun contains 99.87% of the mass, yet only 0.54% of the angular momentum, in the Solar System. In a closed system, such as the cloud of gas and dust from which the Sun formed, mass and angular momentum are both conserved. That conservation would imply that, as the mass concentrated at the center of the cloud to form the Sun, it would spin faster, much like a skater pulling in their arms. The high rotational speed predicted by early theories would have flung the proto-Sun apart before it could form. However, magnetohydrodynamic effects transfer the Sun's angular momentum to the outer solar system, slowing its rotation. Breakdown of ideal MHD, in the form of magnetic reconnection, is thought to be the likely cause of solar flares.
can be quite complex, there is typically one rate-determining enzymatic step that allows this reaction to be modelled as a single catalytic step with an apparent unimolecular rate constant kcat. If the reaction path proceeds over one or several intermediates, kcat will be a function of several elementary rate constants, whereas in the simplest case of a single elementary reaction (e.g. no intermediates) it will be identical to the elementary unimolecular rate constant k2. The apparent unimolecular rate constant kcat is also called turnover number, and denotes the maximum number of enzymatic reactions catalysed per second. The Michaelis–Menten equation describes how the (initial) reaction rate v0 depends on the position of the substrate-binding equilibrium and the rate constant k2.
Sources: en.wikipedia.org
There is some difficulty over the correct name of the capital. Early despatches contain reference to both Port Stanley and Stanley. Port Stanley was accepted by the Naming Commission set up in 1943 to consider the names then being included on the War Office maps. Local opinion differs on the matter, but there is no doubt that Stanley is now common usage and has been for some considerable time. The capital is defined as Stanley in the Interpretation and General Law Ordinance. In the circumstances I would advise that the correct name for the capital is Stanley.
== Synthetic biomolecular condensates == Biomolecular condensates can be synthesized for a number of purposes. Synthetic biomolecular condensates are inspired by endogenous biomolecular condensates, such as nucleoli, P bodies, and stress granules, which are essential to normal cellular organization and function. Synthetic condensates are an important tool in synthetic biology, and have a wide and growing range of applications. Engineered synthetic condensates allow for probing cellular organization, regulating cellular physiology, facilitating metabolic pathways, and enable the creation of novel functionalized biological materials, which have the potential to serve as drug delivery platforms and therapeutic agents.
They invented a stochastic corrector model that assumed that replicative templates compete within compartments, and selective values of these compartments depend on the internal composition of templates. Numerical simulations showed that when stochastic effects are taken into account, compartmentalization is sufficient to integrate information dispersed in competitive replicators without the need for hypercycle organization. Moreover, it was shown that compartmentalized hypercycles are more sensitive to the input of deleterious mutations than a simple package of competing genes. Nevertheless, package models do not solve the error threshold problem that originally motivated the hypercycle.
Sources: en.wikipedia.org
The act of signing up participants into a study. Generally this process involves evaluating a participant with respect to the eligibility criteria of the study and going through the informed consent process. (NLM) Epidemiology
=== Caribbean and West Indies === The soybean arrived in the Caribbean in the form of soy sauce made by Samuel Bowen in Savannah, Georgia, in 1767. It remains only a minor crop there, but its uses for human food are growing steadily.
chemical formula Any of various means of concisely displaying information about the chemical composition of a compound or molecule using letters, numbers, and/or typographical symbols. Chemical formulas, such as empirical and molecular formulas, can only indicate the identities and numerical proportions of the atoms in a compound and are therefore more limited in descriptive power than chemical names and structural formulas.
=== July === 1 July SpudCells, a type of artificial cell, are publicly announced. A study published in Nature reports that GPNMB-targeted CAR-T cells can target both glioblastoma cells and tumour-associated macrophages, eliminating detectable tumours and producing long-term disease control in preclinical models. Astronomers report the discovery of Gaia23bra b, the first gravitationally bound exoplanet detected by the Transiting Exoplanet Survey Satellite using gravitational microlensing. The planet is a super-Jupiter orbiting a K dwarf about 40,000 light-years from Earth. 6 July – A study presented at the Federation of European Neuroscience Societies Forum finds that multilingualism is associated with a younger estimated brain age, with people speaking four languages showing brain-connectivity patterns corresponding to about 13 years younger than monolingual people. 13 July – Astronomers announce the detection of erythrulose molecules inside a cloud of gas and dust near the centre of the Milky Way, marking the first evidence of sugar in interstellar space. 16 July – Astronomers report the first observationally confirmed atmosphere around a rocky exoplanet within its star's habitable zone, after detecting helium escaping from the upper atmosphere of LHS 1140 b, a super-Earth approximately 49 light-years from Earth. 29 July – Researchers report a previously unrecognised pathological structure in Alzheimer's disease, termed a "mitochondrial plaque": an accumulation of damaged mitochondria within neuronal processes, associated with impaired mitophagy and lysosomal function.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.